{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:48:06Z","timestamp":1782780486230,"version":"3.54.5"},"reference-count":12,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000894","name":"Spinal Muscular Atrophy Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000894","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omta.2026.201754","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:09:02Z","timestamp":1779206942000},"page":"201754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["External controls for rare disease drug development: Lessons for emerging and advanced therapeutic modalities"],"prefix":"10.1016","volume":"34","author":[{"given":"Samuel H.","family":"Hughes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A.","family":"Beretich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Goodspeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Penn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard A.","family":"Valentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3446-9256","authenticated-orcid":false,"given":"Caitlin","family":"McCombs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201754_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104462","article-title":"Addressing global regulatory challenges in rare disease drug development","volume":"30","author":"Costa","year":"2025","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.omta.2026.201754_bib3","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1007\/s43441-025-00791-1","article-title":"Keeping the end in mind: Reviewing U.S. FDA inspections of submissions including real-world data","volume":"59","author":"Grandinetti","year":"2025","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.omta.2026.201754_bib6","article-title":"Rare Diseases: Natural History Studies for Drug Development","year":"2019","journal-title":"Guidance for Industry"},{"key":"10.1016\/j.omta.2026.201754_bib7","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMp2200089","article-title":"Real-World Evidence - Where Are We Now?","volume":"386","author":"Concato","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201754_bib8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/CLEP.S242097","article-title":"Synthetic and External Controls in Clinical Trials - A Primer for Researchers","volume":"12","author":"Thorlund","year":"2020","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.omta.2026.201754_bib12","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s43441-021-00302-y","article-title":"The use of external controls in FDA regulatory decision making","volume":"55","author":"Jahanshahi","year":"2021","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.omta.2026.201754_bib21","author":"Prasad"},{"key":"10.1016\/j.omta.2026.201754_bib23","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.omta.2026.201754_bib24","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omta.2026.201754_bib34","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1182\/bloodadvances.2023011847","article-title":"Roctavian gene therapy for hemophilia A","volume":"8","author":"Samelson-Jones","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.omta.2026.201754_bib38","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201754_bib41","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13023-020-1332-x","article-title":"A roadmap to using historical controls in clinical trials - by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG)","volume":"15","author":"Ghadessi","year":"2020","journal-title":"Orphanet J. Rare Dis."}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26000893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26000893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:41:58Z","timestamp":1782780118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26000893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S3117387X26000893"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201754","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"External controls for rare disease drug development: Lessons for emerging and advanced therapeutic modalities","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201754","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201754"}}